Literature DB >> 7812976

2-Deoxy-D-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor necrosis factor.

H D Halicka1, B Ardelt, X Li, M M Melamed, Z Darzynkiewicz.   

Abstract

It has been reported that the cytotoxic effect of tumor necrosis factor (TNF) on cells of several tumor cell lines was potentiated in culture media lacking glucose. Also, the antitumor effect of TNF was shown to be enhanced in vivo in mice treated with insulin to reduce their blood glucose level. The present study was aimed to reveal whether (a) the administration of the glucose antimetabolite 2-deoxy-D-glucose (2DG) has an effect similar to that of reduction of the extracellular glucose concentration; (b) the combined treatment with TNF and 2DG, similar to TNF alone, leads to apoptosis; and (c) there is a preference of cells in a particular phase of the cell cycle to undergo apoptosis in the presence of these agents. Exponentially growing human histiocytic lymphoma U937 cells were exposed to 0.1-0.5 nM of recombinant human TNF-alpha in the absence and presence of 1.0-5.0 mM 2DG. Analysis of the cell proliferation rates and their viability revealed that cytotoxicity of TNF was markedly potentiated by 2DG. Thus, administration of 1.0 mM 2DG to the cultures treated with 0.3 nM recombinant human TNF-alpha increased by 2-3-fold the percentage of dead cells after 24-72 h. The antimetabolite alone, at that low concentration, showed minimal cytotoxicity. More than additive cytotoxic effects also were seen at 2.5 and 5.0 mM concentrations of 2DG. Apoptosis was identified by typical changes in cell morphology, preferential degradation of internucleosomal DNA, and in situ extensive DNA strand breakage. The number of cells with DNA strand breaks after 24-h incubation was increased from 13% (0.1 nM TNF alone) to 20 or 45% in the presence of 2.5 or 5.0 mM 2DG, respectively. There was no evidence of a significant cell cycle phase preference in induction of apoptosis by combined treatment with recombinant human TNF-alpha and 2DG, although 2DG alone reduced the percentage of cells in S and G2 + M, apparently by arresting cells in G1. These data, along with observations in other cell systems, suggest that simultaneous stimulatory signals for growth induction, presumed to be provided by TNF, and growth suppression (inhibition of glycolysis) may preferentially trigger apoptosis of transformed cells. The data also suggest that 2DG may be an effective adjunct to TNF in the clinic, increasing the antitumor potency of this cytokine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7812976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  2-Deoxy-D-glucose regulates dedifferentiation through beta-catenin pathway in rabbit articular chondrocytes.

Authors:  Seon Mi Yu; Hyun Ah Kim; Song-Ja Kim
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

Review 2.  Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants.

Authors:  Toshiki Tanaka; H Dorota Halicka; Xuan Huang; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2006-09-01       Impact factor: 4.534

3.  Citrate kills tumor cells through activation of apical caspases.

Authors:  Björn Kruspig; Azadeh Nilchian; Sten Orrenius; Boris Zhivotovsky; Vladimir Gogvadze
Journal:  Cell Mol Life Sci       Date:  2012-10-10       Impact factor: 9.261

4.  Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.

Authors:  Andrean L Simons; Melissa A Fath; David M Mattson; Brian J Smith; Susan A Walsh; Michael M Graham; Richard D Hichwa; John M Buatti; Ken Dornfeld; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

5.  Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression.

Authors:  L R Sorbara; F Maldarelli; G Chamoun; B Schilling; S Chokekijcahi; L Staudt; H Mitsuya; I A Simpson; S L Zeichner
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG.

Authors:  Bhushan S Pattni; Aditi Jhaveri; Ivy Dutta; James D Baleja; Alexei Degterev; Vladimir Torchilin
Journal:  Int J Pharm       Date:  2017-08-24       Impact factor: 5.875

Review 7.  TNF-induced signaling in apoptosis.

Authors:  P C Rath; B B Aggarwal
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.542

8.  Novel strategies of protecting non-cancer cells during chemotherapy: are they ready for clinical testing?

Authors:  Zbigniew Darzynkiewicz
Journal:  Oncotarget       Date:  2011-03

Review 9.  Drugging the addict: non-oncogene addiction as a target for cancer therapy.

Authors:  Remco Nagel; Ekaterina A Semenova; Anton Berns
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

10.  Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.

Authors:  Kazumasa Sekihara; Kaori Saitoh; Lina Han; Stefan Ciurea; Shinichi Yamamoto; Mika Kikkawa; Saiko Kazuno; Hikari Taka; Naoko Kaga; Hajime Arai; Takashi Miida; Michael Andreeff; Marina Konopleva; Yoko Tabe
Journal:  Oncotarget       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.